TGFBR1 and glioblastoma: Consequently, the anti-TGFβ latency-associated peptide antibody can enhance antitumor immune responses in murine glioblastoma models (71); miR-142-3p targeting the TGFβR1 on M2 macrophages results in glioblastoma growth inhibition (28), and targeting the TGFβ-integrin axis improves NK cell antiglioblastoma activity (72).